Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06598800 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors

StatusRecruiting
PhasePhase 1
Started2024-10-18
View on ClinicalTrials.gov ↗

Amendment history

2026-09-10
Study Status, Contacts/Locations v27
Trial sites expanded: 30 → 34 locations
2026-08-06
Study Status, Contacts/Locations v26
Trial sites expanded: 26 → 30 locations
2026-05-28
Study Status, Contacts/Locations v25
Study sitesdetails revised at 1 of 26 sites
2026-05-19
Study Status, Sponsor/Collaborators, Study Description, Study Design, Arms and Interventions, Outcome Measures, Eligibility, Contacts/Locations, IPDSharing v24
Enrollment increased: 87 → 153 participants
Sponsor changed: BeiGene → BeOne Medicines+8 characters
WasBeiGene
NowBeOne Medicines
Eligibility criteria+90 characters
[...] d unresectable solid tumors who have been previously treated, including but not limited to non-small cell lung cancer (NSCLC), colorectal cancer (CRC). ≥ 1 measurable or nonmeasurable lesion as assessed by RECI [...]
Secondary endpoints10 to 9 entries
Phase 1a and 1b: Number of participants with anti-drug antibodies (ADAs) to BG-T187
Study description+209 characters
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
2026-03-11
Study Status v23
Re-verified, no change to tracked fields
Show 22 earlier versions
2026-02-19
Study Status, Contacts/Locations v22
Study sites25→26
2026-02-09
Study Status, Contacts/Locations v21
Study sites24→25
2026-01-21
Study Status, Contacts/Locations v20
Study sites22→24
2026-01-15
Study Status, Contacts/Locations v19
Study sites21→22
2026-01-05
Study Status, Contacts/Locations v18
Study sites17→21
2025-12-15
Study Status, Contacts/Locations v17
Study sites16→17
2025-11-20
Study Status, Oversight, Arms and Interventions, Outcome Measures, Eligibility, Contacts/Locations v16
Primary completion date2028-01-31→2028-09-30
Completion date2028-01-31→2028-09-30
Study sites15→16
Study arms3→5
InterventionsDrug: BG-T187 (Drug)→Drug: BG-T187 (Drug), Other Therapeutic Agents (Drug)
Eligibility criteria+32 characters
[...] ny study-specific procedures, sampling, or data collection. PatientsParticipants must be ≥ 18 years of age or the legal age of consent in th [...] , or carcinoma in situ of the cervix or breast). History of interstitial lung disease (ILD) or noninfectious pneumonitis requiring steroids or other im [...]
Secondary endpoints10 entries, revised
Phase 1a and 1b: Maximum observed plasma concentration (Cmax) of BG-T187 Phase 1a and 1b: Area Under the Plasma Concentration-time Curve (AUC) of BG-T187 Phase 1a and 1b: Terminal Half-Life (t1/2) of BG-T187 Phase 1a and 1b: Time to maximum plasma concentration (Tmax) of BG-T187
Primary endpoints6 to 5 entries
Phase 1a: Maximum Administered Dose (MAD) of BG-T187 Phase 1a:or Maximum Tolerated Dose (MTD) of BG-T187
2025-10-23
Study Identification, Study Status, Contacts/Locations v15
Study sites29→15
2025-09-12
Study Status, Contacts/Locations v14
Study sites26→29
2025-08-19
Active, Not Recruiting→Recruiting Study Status, Contacts/Locations v13
Trial statusActive, Not Recruiting→Recruiting
Study sites20→26
2025-08-05
Study Status, Contacts/Locations v12
Study sites19→20
2025-06-05
2 amendments v10-v11
2 re-verifications since 2025-05-07, no change to tracked fields
2025-05-06
Recruiting→Active, Not Recruiting Study Status, Contacts/Locations v9
Trial statusRecruiting→Active, Not Recruiting
Study sitesdetails revised at 19 of 19 sites
2025-04-30
Study Status, Contacts/Locations v8
Study sitesdetails revised at 1 of 19 sites
2025-04-10
Study Status, Contacts/Locations, IPDSharing v7
Study sitesdetails revised at 5 of 19 sites
2025-03-24
Study Status, Contacts/Locations v6
Study sitesdetails revised at 3 of 19 sites
2025-02-17
Study Status, Contacts/Locations v5
Study sitesdetails revised at 1 of 19 sites
2025-01-31
Study Status, Contacts/Locations v4
Study sites11→19
2025-01-13
Study Status, Contacts/Locations v3
Study sitesdetails revised at 3 of 11 sites
2024-11-27
Study Status, Contacts/Locations v2
Study sites2→11
2024-10-18
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2024-10-11→confirmed 2024-10-18
Study sites0→2
2024-09-12
Original filing
This is a first-in-human (FIH), Phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-T187 alone and in combination with other therapeutic agents in participants with advanced solid tumors.
Trial Details
NCT Number NCT06598800
Lead Sponsor BeOne Medicines
Conditions Advanced Solid Tumor
Enrollment 153 participants
Start Date 2024-10-18
Primary Completion 2028-09-30 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-09-11